Blog Category:

Seamless ATT Implementation: Institution and Pharmacy Developed Protocols, Safety, and Real-World Workflow Solutions

Alzheimer’s disease (AD) is an escalating public health challenge, with rising prevalence and profound burdens on patients, caregivers, and healthcare systems. Recent approvals of amyloid-targeting therapies (ATTs) represent a major advancement in disease-modifying treatment for early symptomatic AD. However, translating …

Leading the Conversation: Pharmacy-Driven Strategies for Shared Decision-Making in ATT Care

Alzheimer’s disease (AD) continues to impose a growing public health burden as prevalence rises alongside an aging population. Despite advancements in diagnostic tools and the emergence of Alzheimer’s-targeted therapies (ATTs), many healthcare professionals (HCPs) face challenges in integrating new evidence …

From Trial Data to Treatment Decisions: Pharmacy-Supported Stepwise Patient Selection for ATT Success

Alzheimer’s disease (AD) remains a leading cause of cognitive decline and functional impairment in older adults, with early diagnosis and intervention offering the greatest opportunity to preserve quality of life. The emergence of novel disease-modifying, amyloid-targeting therapies (ATTs) has created …

What’s Your Protocol? Streamlining Oncology/Pathology Collaboration Throughout the BC Journey

As HER2-low and ultralow classifications reshape metastatic breast cancer (mBC) treatment pathways, many practices still face real-world barriers to accurate testing and timely reporting. Intra-laboratory variability, limited uptake of emerging assays, and fragmented communication across care teams can all lead …

Decoding the ATT Landscape: Mechanisms, Evidence, and the Evolving Role of Pharmacy

Alzheimer’s disease (AD) affects more than 55 million individuals worldwide, leading to progressive decline in memory, cognition, and ability to perform activities of daily living (ADLs). Recent advancements in amyloid-targeting therapies (ATTs) have created new opportunities to alter disease progression …

Case Closed? Diagnosing Idiopathic Hypersomnia Beyond the Usual Suspects

Idiopathic hypersomnia (IH) is a life-disrupting condition characterized by excessive daytime sleepiness (EDS) that makes waking up a daily struggle, limits productivity, and erodes overall quality of life. For many patients with IH, the journey to diagnosis is long and …

Spotlight on LN: Early Detection Meets Personalized Care

Health care professionals involved in lupus nephritis (LN) care face challenges in recognizing early signs of renal involvement in systemic lupus erythematosus, navigating an increasingly expanding treatment landscape, and addressing persistent disparities affecting Black and Latine patients. Missed or delayed …

Bridging the Gaps – Advancing Equity and Multidisciplinary LN Management

Health care professionals (HCPs) managing lupus nephritis (LN) face persistent gaps in equitable care, with disproportionate burden and worse outcomes among Black and Latine patients driven by structural barriers, delayed recognition, and inconsistent access to specialty services. Despite updated guidelines …

Partnering for Success – Patient Engagement and PrEP Adherence Strategies

Across diverse global settings, patient engagement and sustained adherence remain major challenges in HIV prevention, particularly with pre-exposure prophylaxis (PrEP). Barriers such as insufficient provider training in communication strategies, in addition to broader issues such as stigma, limited health literacy, …